tbuckley/cabot-search huggingface dataset:
SAT0303 Trabecular Bone Score and Bone Mineral Density in Ukrainian Men with Vertebral Fractures
Authors: V. Povoroznyuk, A. Musiienko
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Traditionally BMD has been considered a major determinant of bone strength. However, it is shown that the bone strength and fracture risk depend on several parameters: macrogeometry of cortical bone, BMD, trabecular bone microarchitecture, bone microdamage, bone mineralization, and bone metabolism. Previous studies have found a significant decrease in the quality of trabecular bone of men while they9re ageing. Nevertheless, the trabecular bone score of the Ukrainian men with osteoporotic vertebral fractures has not yet been studied. <h3>Objectives</h3> The aim of this study is to evaluate the trabecular bone score (TBS) and bone mineral density (BMD) in men with osteoporotic vertebral fractures. <h3>Methods</h3> We9ve examined 243 men aged 30-89 years, divided according to the gerontologic classification: 30-44 yrs (n=46), 45-59 yrs (n=83), 60-74 yrs (n=86), 75-89 yrs (n=28). The basic group consists of 52 men with osteoporotic vertebral fractures in the anamnesis (mean age – 59.8±13.7 yrs; mean height – 1.73±6.98 m; mean weight – 79.0±14.9 kg) and control group - of 191 men without fractures (mean age – 57.4±13.7 yrs; mean height – 1.74±6.89 m; mean weight – 76.5±9.3 kg). The BMD of PA lumbar spine and proximal femur were measured by the DXA method (Prodigy, GEHC Lunar, Madison, WI, USA) and PA spine TBS were assessed by the TBS iNsight® software package installed on our DXA machine (Med-Imaps, Pessac, France). <h3>Results</h3> We have observed a significantly lower TBS (L<sub>1</sub>-L<sub>4</sub>) in the basic group (30-44 yrs – 1.083±0.187, 45-59 yrs – 1.025±0.248, 60-74 yrs – 1.084±0.170, 75-89 yrs – 0.951±0.170) as compared to the control group (30-44 yrs – 1.276±0.121, 45-59 yrs – 1.226±0.156, 60-74 yrs – 1.150±0.175, 75-89 yrs – 1.183±0.174); F =1.56; p&lt;0.001. We also found the lower BMD of lumbar spine in the basic group of patients – 30-44 yrs – 0.981±0.125 g/cm<sup>2</sup>, 45-59 yrs – 1.028±0.184 g/cm<sup>2</sup>, 60-74 yrs – 1.014±0.158 g/cm<sup>2</sup>, 75-89 yrs – 0.970±0.183 g/cm<sup>2</sup> (F =1.52; p&lt;0.001) and of the proximal femur – 30-44 yrs – 0.854±0.149 g/cm<sup>2</sup>, 45-59 yrs – 0.873±0.139 g/cm<sup>2</sup>, 60-74 yrs – 0.823±0.136 g/cm<sup>2</sup>, 75-89 yrs – 0.716±0.107 g/cm<sup>2</sup> (F =1.10; p&lt;0.001) compared to the control group. <h3>Conclusions</h3> Subjects with vertebral fractures have TBS and BMD parameters significantly lower than the healthy men. <h3>Disclosure of Interest</h3> None declared
AB0401 Anxiety and Depression in Patients with Rheumatoid Arthritis Treated with Biological Drugs: Prevalence and Relationship with Disease Activity
Authors: V. Grosso, F. De Nard, S. Breda, S. Monti, M. Todoerti, R. Caporali, C. Montecucco
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Many patients with rheumatoid arthritis (RA) experience anxiety and depression, with higher presence of these disorders in those with poorer outcome [1]. Previous experiences found relationships with psychological status and disease activity in patients with active disease [2,3]. Further evidences are needed to asses the impact on residual RA activity during treatment. <h3>Objectives</h3> To register the prevalence of anxious (ANX) and depressive (DEP) disorders in RA patients treated with bDMARDs with stable disease and therapy and to evaluate their connection with disease activity. <h3>Methods</h3> We assessed the presence of ANX and DEP disorders with the HADS questionnaire [4] in patients with RA treated according the EULAR 2013 recommendations with bDMARDs [5]. We registered disease activity using DAS28 score during the same day of questionnaire compiling. Patients with major changes in their DMARD therapy during the previous six months, with known diagnosis of anxiety-depressive syndrome, fibromyalgia, or treated with antidepressant drugs were excluded. The variables of interest were compared between groups with Kruskall-Wallis test. <h3>Results</h3> We assessed 200 patients, female 171 (85%), with an overall median (IQR) age and disease duration of 62,35 (54,09 – 76,03) years and 11,24 (7,29 – 19,46) years respectively. At least one ANX or DEP disorder was present in 93 (46.5%) patients. In patients with ANX, DEP and with ANX*DEP disorders values of pain VAS, DAS28, GH, PGA, number of painful joints on 28 (TND28), HAQ were higher than those in HEALTY group (p&lt;0,01). Prednisone dosage was higher among patients with ANX or DEP disorders. Number of swollen joints on 28 (SWJ28) CRP and ESR were not different among groups. There was a moderate correlation between HADS scores and DAS28, pain VAS, PGA, GH and TND28. <h3>Conclusions</h3> There is a high prevalence of ANX and DEP disorders in patients with RA. Patients with those disorders have higher level of residual disease based on higher subjective variables, while objective variables (SWJ28 and laboratory indexes) remain unmodified. The higher steroid doses in patients with ANX or DEP are probably due to higher disease activity measured with DAS28. <h3>References</h3> Matcham F et al, Rheumatology (Oxford) 2013. Traki L et al, Clin Rheumatol 2014. Cordingley L et al, Arthritis Care Res (Hoboken) 2014. Zigmond AS et al, Acta Psychiatr Scand 1983. Smolen JS et al, Annals Rheum Dis 2014. <h3>Disclosure of Interest</h3> None declared
Abstract 2194: p21Waf1/Cip1dependent chromatin modifications in colorectal tumor cells
Authors: Pablo Lennert, Katharina Erlenbach-Wuensch, Carsten Kroeger, Sara Steinmann, Kerstin Huebner, Sushmita Paul, Felix Rausch, Arndt Hartmann, Regine Schneider-Stock
Journal: Cancer Research (2015)

Abstract Objectives: The cell cycle regulator p21Waf1/Cip1 belongs to the family of cyclin-dependent kinase inhibitors (CDKIs). Depending on the cellular condition, p21Waf1/Cip1 can either, inhibit the cell cycle or promote proliferation, prohibit or induce apoptosis and increase or decrease cell differentiation. The contradictory nature of p21Waf1/Cip1 encouraged us to investigate the effects of this CDKI on the expression of chromatin modifying enzymes in colorectal tumor cells. Methods: Three different HCT116 cell lines were used for our studies. HCT116 WT, HCT116 p21-/- and HCT116 p53-/-. The isolated RNA was analyzed via Epigenetic Chromatin Modification Enzymes RT2 Profiler PCR Arrays from Qiagen. Western Blot analysis was performed to verify the results of the PCR arrays. In addition, immunohistochemical staining of different chromatin modifiers was performed on tissue microarrays of colon cancer patients. The protein structure of p21Waf1/Cip1 was generated by computational modelling techniques to investigate possible interactions between p21Waf1/Cip1 and chromatin modifying enzymes. Ex vivo crypt organoids from WT and p21 -/- mice were studied for chromatin signature. Results: The PCR arrays provided us with astonishing results. Compared to the wild type HCT116 cells, we could see a clear deregulation of a high number of different chromatin modifying enzymes in the two knock out cell lines. SETD1B was up-regulated 1,8 times in p21-/- and HDAC1, which is a known interaction partner of p21Waf1/Cip1, was down regulated about 2 times compared to the WT cells. This could also be proven by Western Blot and immunohistochemical analysis. The data was further processed and analyzed using an R package termed as HTqPCR and it was observed that ATF2 was up-regulated, while AURKB, different HDACs, and DNMT3B genes were down-regulated in p21-/- cells compared to the WT cells. The interaction between p21Waf1/Cip1 and HDAC1 could be analyzed on an atomic scale by molecular dynamics simulations. Conclusion: Our data strongly suggests that p21Waf1/Cip1 is very important for chromatin regulation in colon cancer cells and that its loss induces an active histone code. Interestingly most p21-dependent effects were independent of p53. These exciting and new findings have to be further investigated. Citation Format: Pablo Lennert, Katharina Erlenbach-Wuensch, Carsten Kroeger, Sara Steinmann, Kerstin Huebner, Sushmita Paul, Felix Rausch, Arndt Hartmann, Regine Schneider-Stock. p21Waf1/Cip1 dependent chromatin modifications in colorectal tumor cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2194. doi:10.1158/1538-7445.AM2015-2194
PTU-003 Flexible endoscopic diverticulotomy is a safe and viable treatment for zenker’s diverticulum: a video case series
Authors: K Kandiah, F Chedgy, R Bhattacharyya, P Bhandari
Journal: Gut (2015)

<h3>Introduction</h3> Zenker’s diverticulum is a sac-like outpouching of the mucosa and submucosa through an area of muscular weakness between the thyropharyngeus and cricopharyngeus muscles. Traditional treatments have been surgical with open or intraluminal approaches to cricopharyngeal myotomy where the overall complication rate is 9.6%. An alternative approach is to use a flexible endoscope to perform a diverticulotomy. We present a video series to illustrate the principles of flexible endoscopic diverticulotomy. <h3>Method</h3> We reviewed prospectively collected data of patients with Zenker’s diverticulum referred to our department for endotherapy between January 2014 and January 2015. All patients had Zenker’s diverticulum confirmed on barium swallow. Every procedure was carried out under general anaesthesia by a single endoscopist (PB). A guide wire is inserted into the stomach under direct vision, over which a double-lipped overtube (ZD overtube, ZDO-22–30; Cook Endoscopy, Winston-Salem, North Carolina) is threaded. Under direct vision, the overtube is advanced until the long flap is positioned in the oesophageal lumen and the short flap is in the diverticulum. The septum is clearly visualised and stabilised between the two flaps. The septal mucosa is cut in the middle using a needle knife or diathermy scissors. The mucosal incision is extended until the cricopharyngeal muscle fibres are completely incised. Following this, the cut is extended to approximately 1 cm from the base. Prophylactic endoclips are placed to prevent perforation or bleeding. Patients resume a liquid diet 12 h post procedure. <h3>Results</h3> A total of 5 patients underwent flexible endoscopic diverticulotomy [female 3, median age 76 years (range 69–84 years)]. 2 patients had previous failed surgical interventions. The mean size of diverticulae was 48 mm (range 30–70 mm) and the mean duration of each procedure was 33 min (range 30–40 mins). 1 patient required an overnight stay as he lived outside our catchment area. There were no procedure related complications or mortality. All patients were able to drink within 12 h and start on a soft diet within 48 h post procedure. Prior to the diverticulotomy, 80% of patients experienced dysphagia with every meal and 60% suffered with regurgitation several times a week. All patients were asymptomatic at follow up at 3. Where 12-month data is available, all patients (3/5) remain asymptomatic. <h3>Conclusion</h3> In expert hands, flexible endoscopic diverticulotomy is a novel, and safe treatment for Zenker’s diverticulum. It obviates the need for invasive surgery and a majority of patients can be treated on a day-case basis. Initial results are encouraging with no reported complications and excellent short-term success rates. <h3>Disclosure of interest</h3> None Declared.
PTH-055 A 17-year prospective cohort study of paediatric inflammatory bowel disease patients diagnosed less than 10 years of age (paris a1a)
Authors: P Henderson, P Rogers, DC Wilson
Journal: Gut (2015)

<h3>Introduction</h3> The recently published paediatric inflammatory bowel disease (PIBD) Paris classification highlights that patients diagnosed before their 10<sup>th</sup>birthday (Paris A1a) have a different clinical phenotype at presentation than those diagnosed aged 10–16 years (A1b). However, data regarding accurate incidence rates, disease natural history, medication use and surgery in the A1a group is lacking. <h3>Method</h3> All A1a PIBD patients within our prospective, regional PIBD database from South-East Scotland (SES) diagnosed from 08/97–07/14 had data recorded regarding demographics, phenotype data, details of medical therapy and surgery; data at last paediatric follow-up (FU) was also collected. Accurate incidence data was generated using publicly available population data for SES. Statistics were performed in GraphPad Prism and R with Poisson regression analysis for incidence data. <h3>Results</h3> 121 A1a PIBD patients (77 Crohn’s disease [CD], 28 ulcerative colitis [UC] and 16 IBD-unclassified [IBDU]) were identified in the 17 yr period (31% of entire PIBD cohort); 52% were male. Median FU was 7.1yrs (IQR 3.6–9.6). The incidence of A1a PIBD during 2000–2013 was 4.4/100,000/yr (CD 2.8/100,000/yr; UC 1.0/100,000/yr; IBDU 0.6/100,000/yr); there was no significant increase in incidence between 2000–2006 and 2007–2013 (p = 0.577). At diagnosis 20% of CD patients diagnosed at 2–5 yrs had panenteric disease, 36% isolated colonic disease, and 16% had isolated oral and/or perianal disease; all had inflammatory behaviour. At prolonged FU phenotype was stable. In the older CD cohort (6–9 yrs) 41% had panenteric disease at diagnosis (45% at FU), 25% had isolated colonic disease, and 17% of this group progressed to penetrating/fistulising disease at follow-up. The older age-group were more likely to have panenteric disease at diagnosis (p = 0.002) or progress to penetrating disease (p &lt; 0.001). A1a patients were exposed to immunosupressive therapy and had surgery performed later after diagnosis than A1b patients (p &lt; 0.05); successful remission at anti-TNF therapy induction was achieved in 57% of patients. 20 patients (17%) had IBD-related surgery while in paediatric services. <h3>Conclusion</h3> A third of patients are diagnosed with PIBD present before 10 years of age, with the incidence of very early-onset disease remaining stable in recent years. The requirement for immunosuppression, especially biological therapy, is significant and represents a high disease burden in these patients. Intriguingly, differences exist between those diagnosed at 6–9 years in that they are exposed to immunosuppressants and undergo surgery sooner after diagnosis and are more likely to have panenteric CD at diagnosis and to progress to penetrating disease. <h3>Disclosure of interest</h3> None Declared.
Screening for Chlamydia trachomatis
Authors: I Simms, G Hughes, M Catchpole, C Thompson, H. Maiti, H. Bower, J. Norrie, M. Polaneczky, A A Opaneye
Journal: BMJ (1998)

Hypoxic responses in infants Subjecting infants to low oxygen concentrations seems unethicalEditor-The ethics of Parkins et al's study depend partly on whether there is any potential benefit to the infants from the experiment. 1 If parents subject their infant to low oxygen concentrations in an aeroplane they take a risk which is balanced against the benefit of air travel.Unless there is some real prospect of identifying infants at risk and offering useful protection against the sudden infant death syndrome, it seems to me to be unethical to subject those infants to the risk of exposure to low oxygen concentration.The fact that some of the families had previously experinced the loss of a child may have increased the likelihood of compliance.This makes me even more worried about the ethics of the study.
Meteorological and climate change themes at the 2010 International Conference on Emerging Infectious Diseases
Authors: N Wilson, D Lush, M G Baker
Journal: Eurosurveillance (2010)

This report outlines selected highlights of presentations that took place at the 2010 International Conference on Emerging Infectious Diseases (ICEID) [1], held between 11 and 14 July 2010 at the Hyatt Regency Atlanta in Atlanta, Georgia, United States (US). The conference was organised by five national and international bodies and was attended by over 1,600 participants from a wide range of professional backgrounds. Abstracts for the posters and slide sessions have been published [2].
THU0113 Differing Isotypes of the Anti-Citrullinated Peptide/Protein Antibodies in Palindromic Rheumatism and Rheumatoid Arthritis: Table 1.
Authors: S.R. Cabrera Villalba, M.J. Gomara, J. Ramirez, G. Salvador, V. Ruiz-Esquide, M.V. Hernandez, J. Inciarte-Mundo, A. Cuervo, J. Cañete, R. Sanmarti
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Palindromic rheumatism (PR) is an intermittent arthritis, may evolve to rheumatoid arthritis (RA), particularly in patients with citrullinated peptide/protein antibodies (ACPA), but not all patients progress to RA. Differences in ACPA isotypes have been shown between patients with established and preclinical RA. It is unclear whether ACPA isotypes differ between patients with longstanding PR and RA. <h3>Objectives</h3> To determine whether there are differences in the recognition of epitopes between patients with longstanding PR and established RA by analysis of different ACPA fine specificities and isotypes <h3>Methods</h3> Case-control study. Cases: patients with pure PR, with no evolution to RA or other rheumatic disease at study entry. Controls: patients with established RA (ACR-87) matched by sex, disease duration and ACPA positivity (commercial CCP2 test [Eurodiagnostica]; NV&lt;50U). ACPA specificity in sera was determined by ELISA tests using different synthetic citrullinated peptides as antigens: [Cit 630] α-Fibrin (617-631), [Cit 64,69,71] Vimentin (47-72) and <i>S</i><sup>4</sup>, <i>S</i><sup>22</sup> cyclo [Cys 4,22, Cit 9,15] Enolase (5-21), namely p18, p55 and CEP-1, respectively. The cut off for each ELISA test was established by ROC curves, with a specificity of 98% compared to a healthy population (blood donors, n=64). The presence and number of different ACPA isotypes (IgA,IgG,IgM) in both groups was analyzed. <h3>Results</h3> We included 108 patients: 54 PR and 54 RA. 62.9% were female and 66.7% in both groups were CCP2 positive. No significant differences between groups in mean age (51.2±11.3 y vs 54.7±11.8 years) and disease duration (11.6±10.7 y vs. 8.3±6.1 years) were found. PR patients had a lower frequency of ACPA isotypes than RA, which was significant in the case of IgA and IgM against p18 (PR-IgA 18.5% vs RA-IgA 51.8%; p&lt;0.001, and PR-IgM 13% vs 38.9% RA-IgM; p&lt;0.001) and in IgA and IgG isotypes against p55 (PR-IgA 16.7% vs RA-IgA 38.9%; p&lt;0.01, PR-IgG 24.1% vs RA-IgG 59.3%; p&lt;0.001) (see Table 1). The mean number of ACPA isotypes was lower in PR than in RA patients. <h3>Conclusions</h3> Patients with PR had a lower frequency of isotypes of ACPA than RA patients, especially in the case of p18 (isotypes IgA and IgM) and p55 (isotypes IgA and IgG). PR patients with fewer ACPA isotypes may have a better prognosis and without progression to RA. <h3>Disclosure of Interest</h3> None declared
Sainsbury Report.
Authors: H A Sloot
Journal: BMJ (1967)

PointersRh-haemolytic Disease: Genetic studies in Swallowtail butterflies led to the Liverpool team's interest in the Rh blood groups, culmina- ting in clinical trials in which rhesus-negative mothers were successfully protected by anti-D gammaglobulin against immunization (p. 7).Leader at p. 3. Death from a Broken Heart: Results of a survey in a semi-rural area confirmed statistically that there is a relation between bereavement, especially at home, and death of close relatives within the succeeding year (p.13).Leader at p. 2.Infection in the Theatre: Outbreak of Staph.aureus wound infection traced to anaesthetist suffering from psoriasis and carrying and dis- seminating the same strains of organism (p.
Herpes-Like Simian Viruses: Retrospective and Prospective Considerations&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Thomas H. Weller, M.D.
Journal: JNCI Journal of the National Cancer Institute (1972)

Herpes-Like Simian Viruses: Retrospective and Prospective Considerations Get access Thomas H. Weller, M.D. Thomas H. Weller, M.D. Richard Pearson Strong Professor of Tropical Public Health and Chairman of the Department, Harvard School of Public Health, Boston, Massachusetts 02115 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 49, Issue 1, July 1972, Pages 209–212, https://doi.org/10.1093/jnci/49.1.207 Published: 01 July 1972
Comparison of Posthospitalization Function and Community Mobility in Hospital Mobility Program and Usual Care Patients
Authors: Cynthia J. Brown, Kathleen T. Foley, John D. Lowman, Paul A. MacLennan, Javad Razjouyan, Bijan Najafi, Julie Locher, Richard M. Allman
Journal: JAMA Internal Medicine (2016)

Low mobility is common during hospitalization and associated with loss or declines in ability to perform activities of daily living (ADL) and limitations in community mobility.To examine the effect of an in-hospital mobility program (MP) on posthospitalization function and community mobility.This single-blind randomized clinical trial used masked assessors to compare a MP with usual care (UC). Patients admitted to the medical wards of the Birmingham Veterans Affairs Medical Center from January 12, 2010, through June 29, 2011, were followed up throughout hospitalization with 1-month posthospitalization telephone follow-up. One hundred hospitalized patients 65 years or older were randomly assigned to the MP or UC groups. Patients were cognitively intact and able to walk 2 weeks before hospitalization. Data analysis was performed from November 21, 2012, to March 14, 2016.Patients in the MP group were assisted with ambulation up to twice daily, and a behavioral strategy was used to encourage mobility. Patients in the UC group received twice-daily visits.Changes in self-reported ADL and community mobility were assessed using the Katz ADL scale and the University of Alabama at Birmingham Study of Aging Life-Space Assessment (LSA), respectively. The LSA measures community mobility based on the distance through which a person reports moving during the preceding 4 weeks.Of 100 patients, 8 did not complete the study (6 in the MP group and 2 in the UC group). Patients (mean age, 73.9 years; 97 male [97.0%]; and 19 black [19.0%]) had a median length of stay of 3 days. No significant differences were found between groups at baseline. For all periods, groups were similar in ability to perform ADL; however, at 1-month after hospitalization, the LSA score was significantly higher in the MP (LSA score, 52.5) compared with the UC group (LSA score, 41.6) (P = .02). For the MP group, the 1-month posthospitalization LSA score was similar to the LSA score measured at admission. For the UC group, the LSA score decreased by approximately 10 points.A simple MP intervention had no effect on ADL function. However, the MP intervention enabled patients to maintain their prehospitalization community mobility, whereas those in the UC group experienced clinically significant declines. Lower life-space mobility is associated with increased risk of death, nursing home admission, and functional decline, suggesting that declines such as those observed in the UC group would be of great clinical importance.clinicaltrials.gov Identifier: NCT00715962.